Loading...

Purified anti-mouse IL-6 Antibody

Pricing & Availability
Clone
MP5-20F3 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-6, B cell stimulating factor-2 (BSF-2), Cytotoxic T cell differentiation factor (CDF), Hepatocyte stimulating factor (HSF), Hybridoma/plasmacytoma growth factor (HPGF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
MouseIL-6_061604
  • MouseIL-6_061604
Cat # Size Price Quantity Check Availability Save
504501 50 µg 83 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
504502 500 µg 138 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-6 is a potent lymphoid cell growth factor that stimulates the growth and survivability of certain B cells and T cells. IL-6 plays a role in host defense, acute phase reactions, immune responses, and hematopoiesis. IL-6 is expressed by T cells, B cells, monocytes, fibroblasts, hepatocytes, endothelial cells and keratinocytes.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
COS-7-expressed, recombinant mouse IL-6
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA Capture - Quality tested
CyTOF® - Verified
ELISPOT Capture, Neut, IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA applications, a concentration range of 0.5 – 2.0 µg/mL is recommended. To obtain a linear standard curve, serial dilutions of mouse IL-6 recombinant protein ranging from 500 to 8 pg/mL are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA Capture1-3,11 or ELISPOT Capture4,5: The purified MP5-20F3 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MP5-32C11 antibody (Cat. No. 504602) as the detecting antibody and recombinant mouse IL-6 (Cat. No. 575709) as the standard. The Ultra-LEAF™ purified antibody is suggested for ELISPOT capture.

Flow Cytometry: The fluorochrome-labeled MP5-20F3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-6 -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.

Neutralization1-2,8-10: The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-6 bioactivity in vivo and in vitro (Cat. No. 504506).

Additional reported applications (for relevant formats of this clone) include: In Vivo Capture7, and immunohistochemical staining (paraformaldehyde-fixed/saponin-treated6, and acetone-fixed frozen tissue sections13, 14).

Note: For testing mouse IL-6 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431301 to 431306) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA Capture, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA Capture)
  4. Fujihashi K, et al. 1991. J. Immunol. Meth. 160:181. (ELISPOT Capture)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT Capture)
  6. Litton M, et al. 1994. J. Immunol Meth. 175:47. (IHC)
  7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons, New York. Unit 6.28. (In Vivo Capture)
  8. Starnes HF Jr, et al. 1990. J. Immunol. 145:4185. (Neut)
  9. Riedemann NC, et al. 2003. J. Immunol. 170:503. (Neut)
  10. Rochman I, et al. 2005. J. Immunol. 174:4761. (Neut)
  11. O'Connell PJ, et al. 2006. Blood 107:1010. (ELISA Capture)
  12. Ozeki Y, et al. 2010. Int. Immunol. 22:179. PubMed
  13. Galie M, et al. 2005. Carcinogenesis 26:1868 (IHC)
  14. Schone MP, et al. 2000. J Immunol 165:6583 (IHC)
  15. Keswani T, et al. 2014. Exp Parasitol. 141:82. PubMed
  16. Notley CA, et al. 2015. J Immunol. 194:1621. PubMed
Product Citations
  1. Xu M et al. 2018. Immunity. 48(4):787-798 . PubMed
  2. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  3. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  4. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  5. Crawford G, et al. 2018. Nat Immunol. 1.388194444. PubMed
  6. Rosen DA, et al. 2019. Sci Transl Med. 11:eaau5266. PubMed
  7. Ji Z, et al. 2019. Front Immunol. 1.722916667. PubMed
  8. Wu G, et al. 2020. Front Oncol. 10:194. PubMed
  9. Daley D, et al. 2017. Nat Med. 23:556. PubMed
  10. Al Sayed MF, et al. 2019. Cancer Res. 79:346. PubMed
  11. Schwaderer J, et al. 2020. Cell Death Dis. 11:154. PubMed
  12. Peterson LW, et al. 2017. J Exp Med. 214:3171. PubMed
  13. Ozeki Y, et al. 2010. Int Immunol. 1.040972222. PubMed
  14. Lee J, et al. 2015. PLoS One. 10: 0142624. PubMed
  15. Zhao L, et al. 2021. STAR Protocols. 2:100732. PubMed
  16. Herrada AA, et al. 2022. Front Immunol. 13:841641. PubMed
  17. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  18. Morita M, et al. 2021. Heliyon. 7:e06228. PubMed
  19. Muraleedharan A, et al. 2021. Glia. 69:697. PubMed
  20. Di Conza G, et al. 2021. Nat Immunol. 22:1403. PubMed
  21. Bahreyni A, et al. 2023. Biomed Pharmacother. 163:114789. PubMed
  22. Bahreyni A, et al. 2023. BMC Med. 21:193. PubMed
  23. Wang J, et al. 2023. Elife. 12:. PubMed
RRID
AB_315335 (BioLegend Cat. No. 504501)
AB_315336 (BioLegend Cat. No. 504502)

Antigen Details

Structure
Neuropoietic cytokine family; 22-29 kD (Mammalian)
Bioactivity
Hematopoiesis; antigen-specific immune responses, inflammatory reactions; acute phase reaction
Cell Sources
T cells, B cells, macrophages, bone marrow stromal cells, fibroblasts, keratinocytes, mesangium, astrocytes, endothelial cells
Cell Targets
T cells, B cells, hepatocytes, cholinergic neurons
Receptors
Heterodimer IL-6Rα (CD126)/IL-6Rβ (CD130; gp130)
Biology Area
Immunology, Innate Immunity
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Hirano T. 1998. Intl. Rev. Immunol. 16:249.
3. Patterson P. 1992. Curr. Opin. Neurobiol. 2:94.
4. Van Oers M, et al. 1993. Ann. Hematology 66:219.

Regulation
Upregulated by IL-1, TNF, PDGF, IFN-β, TNF-α, NGF, IL-17; downregulated by glucocorticoids IL-4, TGF-β
Gene ID
16193 View all products for this Gene ID
UniProt
View information about IL-6 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 05.22.2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account